1. Home
  2. INSM vs WES Comparison

INSM vs WES Comparison

Compare INSM & WES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • WES
  • Stock Information
  • Founded
  • INSM 1988
  • WES 2007
  • Country
  • INSM United States
  • WES United States
  • Employees
  • INSM N/A
  • WES N/A
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • WES Natural Gas Distribution
  • Sector
  • INSM Health Care
  • WES Utilities
  • Exchange
  • INSM Nasdaq
  • WES Nasdaq
  • Market Cap
  • INSM 17.3B
  • WES 15.2B
  • IPO Year
  • INSM 2000
  • WES 2008
  • Fundamental
  • Price
  • INSM $102.68
  • WES $38.56
  • Analyst Decision
  • INSM Strong Buy
  • WES Hold
  • Analyst Count
  • INSM 17
  • WES 5
  • Target Price
  • INSM $106.80
  • WES $40.40
  • AVG Volume (30 Days)
  • INSM 4.1M
  • WES 907.3K
  • Earning Date
  • INSM 08-07-2025
  • WES 08-06-2025
  • Dividend Yield
  • INSM N/A
  • WES 9.44%
  • EPS Growth
  • INSM N/A
  • WES N/A
  • EPS
  • INSM N/A
  • WES 3.34
  • Revenue
  • INSM $381,030,000.00
  • WES $3,634,610,000.00
  • Revenue This Year
  • INSM $28.03
  • WES $5.65
  • Revenue Next Year
  • INSM $120.54
  • WES $3.65
  • P/E Ratio
  • INSM N/A
  • WES $11.54
  • Revenue Growth
  • INSM 20.77
  • WES 11.48
  • 52 Week Low
  • INSM $60.40
  • WES $33.60
  • 52 Week High
  • INSM $102.70
  • WES $43.33
  • Technical
  • Relative Strength Index (RSI)
  • INSM 78.76
  • WES 52.72
  • Support Level
  • INSM $98.46
  • WES $37.90
  • Resistance Level
  • INSM $102.00
  • WES $39.29
  • Average True Range (ATR)
  • INSM 3.50
  • WES 0.70
  • MACD
  • INSM 2.61
  • WES 0.05
  • Stochastic Oscillator
  • INSM 99.61
  • WES 65.07

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

About WES Western Midstream Partners LP Common Units Representing Limited Partner Interests

Western Midstream Partners LP is a USA-based company which own, operate, acquire and develop midstream energy assets. The company through its subsidiary is engaged in the business of gathering, processing, compressing, treating and transporting natural gas, condensate, NGLs and crude oil. It owns or has investments in assets located in the Rocky Mountains (Colorado, Utah, and Wyoming), the Mid-Continent (Kansas and Oklahoma), North-central Pennsylvania and Texas.

Share on Social Networks: